Skip to content


  • Poster presentation
  • Open Access

Rituximab for treatment of severe lupus nephritis

  • 1,
  • 1,
  • 2,
  • 2,
  • 1 and
  • 1
Pediatric Rheumatology20086 (Suppl 1) :P249

  • Published:


  • Systemic Lupus Erythematosus
  • Thrombocytopenia
  • Complete Remission
  • Nephritis
  • Lupus Nephritis


Systemic lupus erythematosus (SLE) is a challenging disease to diagnose and manage. Treatment of lupus nephritis in resistant cases is still a matter of debate.


To investigate the effectiveness of rituximab (Rx) in treatment resistant cases of lupus nephritis.

Materials and methods

Five female patients with a median age of 14 years (range: 12–16 years) with class IV (3/5) and class II (2/5) lupus nephritis were treated with rituximab, steroids and plasmapheresis. Rituximab was given with a dose of 375 mg/m2/week for 4 weeks. Two patients had severe thrombocytopenia, while one of them had developed macrophage activating syndrome. All of them had renal failure with high serum creatinine. ANA and anti ds DNA levels were found to be high in 4 patients with low levels of compleman 3.


Thrombocytopenia was completely resolved at the end of 4 weeks in both patients while only one patient had complete remission of the SLE. Partial remission was observed in two patients and 2 patients did not respond at all.


Rituximab could be effective in treatment of patients with severe, treatment resistant lupus nephritis.

Authors’ Affiliations

Baskent University Department of Pediatric rheumatology and nephrology, Ankara, Turkey
Hacettepe University Department of Pediatric rheumatology and nephrology, Ankara, Turkey


© Baskin et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.